HCPCS code J9347: Tremelimumab-actl, per 1 mg2026 Medicare rate & RVUs in Missouri
Tremelimumab-actl is an intravenous cancer immunotherapy reported per milligram when administered for unresectable liver cancer or metastatic non-small cell lung cancer.
CMS doesn’t publish an office rate for J9347 in Missouri.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9347 covers
Tremelimumab-actl is an immune checkpoint inhibitor administered by intravenous infusion. Oncology clinicians use it with durvalumab for unresectable hepatocellular carcinoma and with durvalumab plus platinum chemotherapy for metastatic non-small cell lung cancer. An oncology practice or hospital outpatient department reports the drug when it furnishes the dose for administration; a qualifying infusion administration is reported separately from the drug.
Each unit represents 1 mg of tremelimumab-actl, so reported units match the total milligrams administered. CMS assigns physician fee schedule status E, excluding the code from that schedule; when Medicare covers the drug, payment is made under another method. CMS classifies it as a Part B drug, generally priced using its quarterly Average Sales Price drug pricing files when covered. The Medicare contractor determines coverage.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9347 pays more and less in Missouri
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Metropolitan Kansas City, MO | Unavailable | Unavailable |
| Metropolitan St. Louis, MO | Unavailable | Unavailable |
| Rest of Missouri | Unavailable | Unavailable |
How the J9347 rate is calculated
Each of J9347’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9347
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9347
J9347 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9347
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9347 isn’t priced in this setting.
J9347 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9173Durvalumab injectionPer 10 mg
- J9173 identifies durvalumab, which may be administered with tremelimumab-actl in a combination regimen. J9347 identifies tremelimumab-actl only.
- J9299NivolumabPer 1 mg
- J9299 identifies nivolumab, a different immunotherapy drug. Select the code for the drug actually furnished; it is not the code for tremelimumab-actl.
- 96413Chemo IV infusionInitial drug, first hour
- 96413 reports a qualifying infusion administration service; J9347 reports tremelimumab-actl in 1 mg units.
J9347 billing questions
How many units should be reported?
Report one unit for each 1 mg of tremelimumab-actl administered. The units should reflect the total administered dose.
Is this the same drug code as durvalumab?
No. J9347 represents tremelimumab-actl; J9173 represents durvalumab, a different drug that may be given with it in a treatment regimen.
Does J9347 include the infusion administration?
No. J9347 identifies the drug. Report a qualifying infusion administration service separately, such as CPT 96413 when applicable.
How does Medicare price and cover J9347?
CMS excludes J9347 from the physician fee schedule under status E. When covered as a Part B drug, it is generally priced using the quarterly ASP drug pricing files, and the Medicare contractor determines coverage.
What documentation supports the units?
Document the drug administered and the total milligrams given so the reported units can be tied to the administered dose.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9347 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist